|
1.
|
Nsihida N, Yano H, Komai K, Nishida T,
Kamura T and Kojiro M: Vascular endothelial growth factor-C and
vascular endothelial growth factor receptor 2 are related closely
to the prognosis of patients with ovarian carcinoma. Cancer.
101:1364–1374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Karavasilis V, Malamou-Mitsi V, Briasoulis
E, Tsanou E, Kitsou E and Pavlidis N: Clinicopathologic study of
vascular endothelial growth factor, thrombospondin-1, and
microvessel density assessed by CD34 in patients with stage III
ovarian carcinoma. Int J Gynecol Cancer. 16(Suppl 1): 241–246.
2006. View Article : Google Scholar
|
|
3.
|
Gómez-Raposo C, Mendiola M, Barriuso J,
Casado E, Hardisson D and Redondo A: Angiogenesis and ovarian
cancer. Clin Transl Oncol. 11:564–571. 2009.
|
|
4.
|
Diniz Bizzo SM, Meira DD, Lima JM, Mororó
Jda S, Casali-da-Rocha JC and Ornellas MH: Peritoneal VEGF burden
as a predictor of cytoreductive surgery outcome in women with
epithelial ovarian cancer. Int J Gynaecol Obstet. 109:113–117.
2010.PubMed/NCBI
|
|
5.
|
Hefler LA, Zeillinger R, Grimm C, et al:
Preoperative serum vascular endothelial growth factor as a
prognostic parameter in ovarian cancer. Gynecol Oncol. 103:512–517.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Zhao Y, Zong ZH and Xu HM: RhoC expression
level is correlated with the clinicopathological characteristics of
ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
Gynecol Oncol. 116:563–571. 2010. View Article : Google Scholar
|
|
7.
|
Weidner N, Folkman J, Pozza F, et al:
Tumor angiogensis: a new significant and independent prognostic
indicator in early stage breast carcinoma. J Natl Cancer Inst.
84:1875–1887. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Brustmann H: Vascular endothelial growth
factor expression in serous ovarian carcinoma: relationship with
topoisomerase II alpha and prognosis. Gynecol Oncol. 95:16–22.
2004. View Article : Google Scholar
|
|
9.
|
Mabuchi S, Kawase C, Altomare DA, et al:
Vascular endothelial growth factor is a promising therapeutic
target for the treatment of clear cell carcinoma of the ovary. Mol
Cancer Ther. 9:2411–2422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Smerdel MP, Waldstrøm M, Brandslund I,
Steffensen KD, Andersen RF and Jakobsen A: Prognostic importance of
vascular endothelial growth factor-A expression and vascular
endothelial growth factor polymorphisms in epithelial ovarian
cancer. Int J Gynecol Cancer. 19:578–584. 2009. View Article : Google Scholar
|
|
11.
|
Verheul HM, Hoekman K, Jorna AS, Smit EF
and Pinedo HM: Targeting vascular endothelial growth factor
blockade: ascites and pleural effusion formation. Oncologist.
5:45–50. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Shen GH, Ghazizadeh M, Kawanami O, et al:
Prognostic significance of vascular endothelial growth factor
expression in human ovarian carcinoma. Br J Cancer. 83:196–203.
2000.PubMed/NCBI
|
|
13.
|
Herr D, Sallmann A, Bekes I, et al: VEGF
induces ascites in ovarian cancer patients via increasing
peritoneal permeability by downregulation of Claudin 5. Gynecol
Oncol. 127:210–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Rudlowski C, Pickart AK, Fuhljahn C, et
al: Prognostic significance of vascular endothelial growth factor
expression in ovarian cancer patients: a long-term follow-up. Int J
Gynecol Cancer. 16(Suppl 1): 183–189. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Fujimoto J, Sakaguchi H, Aoki I, Khatun S
and Tamaya T: Clinical implications of expression of vascular
endothelial growth factor in metastatic lesions of ovarian carcers.
Br J Cancer. 85:313–316. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Bolat F, Gumurdulu D, Erkanli S, et al:
Maspin overexpression correlates with increased expression of
vascular endothelial growth factors A, C and D in human ovarian
carcinoma. Pathol Res Pract. 1:379–387. 2008. View Article : Google Scholar
|
|
17.
|
Shalaby F, Rossant J, Yamaguchi TP, et al:
Failure of blood-island formation and vasculogenesis in
Flk-1-deficient mice. Nature. 376:62–66. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Wang FQ, Barfield E, Dutta S, Pua T and
Fishman DA: VEGFR-2 silencing by interference RNA (siRNA)
suppresses LPA-induced epithelial ovarian cancer (EOC) invasion.
Gynecol Oncol. 115:414–423. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Yen CF, Lee CL, Murk W, Han CM and Liao
SK: Reducing peritoneal vascular endothelial growth factor
concentration and inhibiting cancer scattering in a mouse model of
laparoscopy. Am J Obstet Gynecol. 198:423.e1–423.e7. 2008.
|
|
20.
|
Yagi Y, Fushida S, Harada S, et al:
Biodistribution of humanized anti-VEGF monoclonal
antibody/bevacizumab on peritoneal metastatic models with
subcutaneous xenograft of gastric cancer in mice. Cancer Chemother
Pharmacol. 66:745–753. 2010. View Article : Google Scholar : PubMed/NCBI
|
